This report reviews the current trends and market outlook in China’s pharmaceuticals and health care industry. It also discusses the stock performance and financial highlights for leading players in the sector, including Shanghai Pharma, China National Accord (Sinopharm Accord), Harbin Pharma, Yunnan Baiyao, and Huadong Medicine.
Chinese government spending on health care grew at a compounded annual growth rate (CAGR) of 32.01% between 2005 and 2012. As a result of rising disposable income and health awareness, health care spending per capita in both urban and rural areas is trending up. Nevertheless, public health care expenditure as percentage of total GDP in China still trails many developed economies like the United States, Canada, and Germany.
Revenues from the Chinese pharmaceutical industry grew by a CAGR of 23.3% from 2006 to 2012. The Chinese government has allocated RMB 1.49bn to a subsidy fund to support the development of traditional Chinese medicine in 2013. Chemical drugs preparation, Chinese-prepared medicine, and chemical medicine were the three largest product categories in the pharmaceutical industry in the first half in 2013. Total sales of Chinese-prepared medicines topped more than 90% of total industry revenue in 2012.
• Firms surveyed in this report include Shanghai Pharmaceuticals Holding Co. Ltd. (Shanghai Pharma), China National Accord Medicines Corp. Ltd. (Sinopharm Accord), Harbin Pharmaceutical Group Co. Ltd. (Harbin Pharma), Yunnan Baiyao Group Co. Ltd. (Yunnan Baiyao), and Hangzhou Huadong Medicine Co. Ltd. (Huadong Medicine).
• Health care spending per capita in urban and rural China increased at a CAGR of 9.15% and 18.63%, respectively, between 2004 and 2012.
• Sales of traditional Chinese medicines grew at a CAGR of 21.54% between 2002 and 2012.
• Revenues from the Chinese pharmaceutical industry grew by a CAGR of 23.3% from 2006 to 2012.
Table of Contents
1. Industry Profile
1.1 Market size and value
1.2 Social security and health insurance
1.4 Health care infrastructure
1.4 Pharmaceutical industry overview
1.5 Regulations and policies
2. Market Trends and Outlook
2.1 Social health care insurance system
2.2 Traditional Chinese medicine
2.3 Over-the-Counter (OTC)
3. Leading Players and Comparative Matrix
3.1 Leading players
3.1.1 Shanghai Pharmaceuticals Holding Co. Ltd.
3.1.2 China National Accord Medicines Corp. Ltd.
3.1.3 Harbin Pharmaceutical Group Co. Ltd.
3.1.4 Yunnan Baiyao Group Co. Ltd.
3.1.5 Hangzhou Huadong Medicine Co. Ltd.
3.2 Comparative Matrix
3.3 SWOT Analysis
4. Tables and Charts
Table 1: Number of Beds by Type of Hospital
Table 2: New Drug Classifications in China
Table 3: Top 10 Major Traditional Chinese Medicinal Materials
Table 4: Major Type II Vaccines
Table 5: Shanghai Pharma Financial Highlights
Table 6: Sinopharm Accord Financial Highlights
Table 7: Harbin Pharma Financial Highlights
Table 8: Yunnan Baiyao Financial Highlights
Table 9: Huadong Medicine Financial Highlights
Table 10: Selected Peer Comparison of Key Financial Ratios
Chart 1: Total Government Health Care Expenditure
Chart 2: Total Health Care Expenditure over GDP in 2011
Chart 3: Health Care Expenditure per Capita in Urban and Rural China
Chart 4: Total Government Expenditure on Public Health
Chart 5: Social Security Medical Fund in Urban Areas
Chart 6: Retirees in Urban Areas Insured under Social Security Medical Fund
Chart 7: Health Insurance in China
Chart 8: Number of Hospitals in China
Chart 9: Hospitals by Type
Chart 10: Total Assets of Pharmaceutical Industry in China
Chart 11: Revenue and Net Profit Margin of Pharmaceutical Industry in China
Chart 12: Pharmaceutical Industry Revenue by Product Category 1H2013
Chart 13: Pharmaceutical Market by Therapeutic Area 2011
Chart 14: Accumulated Balance of Social Medical Insurance Programs
Chart 15: Revenue of Traditional Chinese Medicine
Chart 16: Distribution Channel of OTC Pharmaceuticals
Chart 17: Shanghai Pharma Segment Revenue 2012
Chart 18: Sinopharm Accord Segment Revenue 2012
Chart 19: Harbin Pharma Segment Revenue 2012
Chart 20: Yunnan Baiyao Segment Revenue 2012
Chart 21: Huadong Medicine Segment Revenue 2012
Release Date: Mon, 27 Jan 2014